M van Doorn1, A Popma2, T van Amelsvoort3, C McEnery4,5, J F Gleeson5,6, F G Ory7, Jaspers M W M2, M Alvarez-Jimenez4,5, D H Nieman2. 1. Department of Psychiatry, Amsterdam University Medical Centers, Amsterdam, The Netherlands. M.vanDoorn@amsterdamumc.nl. 2. Department of Psychiatry, Amsterdam University Medical Centers, Amsterdam, The Netherlands. 3. Department of Psychiatry and Neuropsychology Maastricht, Maastricht University, Maastricht, The Netherlands. 4. Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia. 5. Orygen, Melbourne, Australia. 6. Australian Catholic University, Melbourne, Australia. 7. Buurtzorg Jong, Almelo, The Netherlands.
Abstract
BACKGROUND: The onset of mental disorders typically occurs between the ages of 12 and 25, and the burden of mental health problems is the most consequential for this group. Indicated prevention interventions to target individuals with subclinical symptoms to prevent the transition to clinical levels of disorders, even leading to suicide, have shown to be effective. However, the threshold to seek help appears to be high. Digital interventions could offer a solution, especially during the Covid-19 pandemic. This implementation study will investigate the digital indicated prevention intervention ENgage YOung people Early (ENYOY), the Dutch version of the original Moderated Online Social Therapy Platform (MOST+) from Australia. In addition, the relationship between stress biomarkers, symptoms and outcome measures of youth using the platform will be investigated in this study. METHODS: The MOST+ platform will be adapted, translated and developed for the situation in the Netherlands in collaboration with a Youth Panel. A prospective cohort of 125 young people (16-25 years) with beginning mental health complaints will be on the platform and followed for a year, of which 10 participants will have an additional smart watch and 10 participants will be asked to provide feedback about the platform. Data will be collected at baseline and after 3, 6 and 12 months. Outcome measures are Psychological Distress assessed with the Kessler Psychological Distress Scale (K10), Social and occupational functioning (measures by the SOFAS), positive mental health indicators measured by the Positive Health Instrument, stress biomarkers with a smart-watch, website journeys of visitors, and feedback of youth about the platform. It will be a mixed-method study design, containing qualitative and quantitative measures. DISCUSSION: This trial will specifically address young people with emerging mental health complaints, and offers a new approach for treatment in the Netherlands. Considering the waiting lists in (child and adolescent)-psychiatry and the increase in suicides among youth, early low-threshold and non-stigmatizing help to support young people with emerging psychiatric symptoms is of crucial importance. Moreover, this project aims to bridge the gap between child and adolescent and adult psychiatry. TRIAL REGISTRATION: Netherlands Trial Register ID NL8966 , retrospectively registered on the 19th of October 2020.
BACKGROUND: The onset of mental disorders typically occurs between the ages of 12 and 25, and the burden of mental health problems is the most consequential for this group. Indicated prevention interventions to target individuals with subclinical symptoms to prevent the transition to clinical levels of disorders, even leading to suicide, have shown to be effective. However, the threshold to seek help appears to be high. Digital interventions could offer a solution, especially during the Covid-19 pandemic. This implementation study will investigate the digital indicated prevention intervention ENgage YOung people Early (ENYOY), the Dutch version of the original Moderated Online Social Therapy Platform (MOST+) from Australia. In addition, the relationship between stress biomarkers, symptoms and outcome measures of youth using the platform will be investigated in this study. METHODS: The MOST+ platform will be adapted, translated and developed for the situation in the Netherlands in collaboration with a Youth Panel. A prospective cohort of 125 young people (16-25 years) with beginning mental health complaints will be on the platform and followed for a year, of which 10 participants will have an additional smart watch and 10 participants will be asked to provide feedback about the platform. Data will be collected at baseline and after 3, 6 and 12 months. Outcome measures are Psychological Distress assessed with the Kessler Psychological Distress Scale (K10), Social and occupational functioning (measures by the SOFAS), positive mental health indicators measured by the Positive Health Instrument, stress biomarkers with a smart-watch, website journeys of visitors, and feedback of youth about the platform. It will be a mixed-method study design, containing qualitative and quantitative measures. DISCUSSION: This trial will specifically address young people with emerging mental health complaints, and offers a new approach for treatment in the Netherlands. Considering the waiting lists in (child and adolescent)-psychiatry and the increase in suicides among youth, early low-threshold and non-stigmatizing help to support young people with emerging psychiatric symptoms is of crucial importance. Moreover, this project aims to bridge the gap between child and adolescent and adult psychiatry. TRIAL REGISTRATION: Netherlands Trial Register ID NL8966 , retrospectively registered on the 19th of October 2020.
Authors: William C Reeves; Tara W Strine; Laura A Pratt; William Thompson; Indu Ahluwalia; Satvinder S Dhingra; Lela R McKnight-Eily; Leslie Harrison; Denise V D'Angelo; Letitia Williams; Brian Morrow; Deborah Gould; Marc A Safran Journal: MMWR Suppl Date: 2011-09-02
Authors: J Angst; D Paksarian; L Cui; K R Merikangas; M P Hengartner; V Ajdacic-Gross; W Rössler Journal: Epidemiol Psychiatr Sci Date: 2015-03-24 Impact factor: 6.892
Authors: Marilon van Doorn; Laurens A Nijhuis; Anne Monsanto; Thérèse van Amelsvoort; Arne Popma; Monique W M Jaspers; Matthijs L Noordzij; Ferko G Öry; Mario Alvarez-Jimenez; Dorien H Nieman Journal: Front Psychiatry Date: 2022-05-25 Impact factor: 5.435